Sarcoma Biology & ‘omics

(P 226) ASSESSING PREDICTIVE VALUE OF RNA-SEQ OF B4GALNT1 AND ST8SIA1 AS BIOMARKERS OF GD2 EXPRESSION IN PEDIATRIC SARCOMAS

(P 227) ASSOCIATION BETWEEN NEUTROPHIL-LYMPHOCYTE RATIO, PLATELET-LYMPHOCYTE RATIO, AND SURVIVAL IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA

(P 228) CHARACTERIZING ORGANELLES IN MYXOFIBROSARCOMA CELLS USING LABEL-FREE OPTICAL DIFFRACTION TOMOGRAPHY

(P 229) CHARACTERIZING THE MICROSATELLITE-BINDING FUNCTION OF EWS-FLI AND ETV6 IN EWING SARCOMA

(P 230) CHARACTERIZING TISSUE-BASED CHANGES DURING AND AFTER RADIOTHERAPY IN MYXOID LIPOSARCOMAS IN THE DOREMY TRIAL

(P 231) COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA

(P 232) DECIPHERING METASTASIS MAINTENANCE AND CHEMO RESISTANCE EVENTS IN CIC-DUX4 SARCOMA

(P 233) DETERMINING THE CONTRIBUTIONS OF PD-L1 AND STAT1 TO THE UPS ANTI-TUMOR MICROENVIRONMENT

(P 234) DNA DAMAGE RESPONSE PATHWAYS IN SYNOVIAL SARCOMA

(P 235) ELUCIDATING THE ONCOGENIC EFFECT OF BCOR-ITD IN SARCOMA

(P 236) EVALUATION OF HISTOLOGIC CHANGES OF TENOSYNOVIAL GIANT CELL TUMORS FOLLOWING TREATMENT WITH PEXIDARTINIB

(P 237) EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION

(P 238) EXPANDING THE MOLECULAR SPECTRUM OF GIANT CELL TUMORS.

(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS

(P 241) INVESTIGATING THE EVOLUTION OF CELL STATES IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING A GENETICALLY ENGINEERED MOUSE MODEL

(P 242) LIPOSARCOMAS WITH 12Q AMPLIFICATION - CAN GENETIC CHANGES DISCLOSE THE DEVELOPMENT AND ORIGIN OF RING CHROMOSOMES?

(P 243) MUTATIONAL ANALYSIS OF PRIMARY AND ADVANCED CHORDOMA TISSUE USING NEXT-GENERATION SEQUENCING

(P 244) MUTATIONAL BURDEN OF COPY NUMBER VARIANTS VS STRUCTURAL VARIANTS IN EXTRASKELETAL MYXOID CHONDROSARCOMA: A CASE STUDY

(P 245) MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS

(P 246) PANOBINOSTAT DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA

(P 247) PROGNOSTIC VALUE OF MITOTIC COUNT IN NON-UTERINE LEIOMYOSARCOMAS: A MONOCENTRIC RETROSPECTIVE STUDY.

(P 248) RESULTS OF A NEOADJUVANT REGIMEN USING A FIXED DOSE OF ADRIAMYCIN AS AN ELECTRON AFFINIC AGENT WITH 27GY FOLLOWED BY WIDE LOCAL RESECTION OF SOFT TISSUE SARCOMAS

(P 249) SARCOMA GENE FUSION BREAKPOINTS: NON-RANDOM EVENT PATTERNS IN SARCOMAS WITH GENE FUSIONS INCLUDING EWING SARCOMA, DSRCT, RHABDOMYOSARCOMA, SYNOVIAL SARCOMA, CCNB3-BCOR, AND CIC-DUX

(P 250) SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY

(P 251) TARGETING SOFT TISSUE SARCOMA CANCER STEM CELLS IMPROVES DOXORUBICIN SENSITIVITY IN VITRO

(P 252) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE

(P 253) THE IMPACT OF CELL FUSION IN LEIOMYOSARCOMA ONCOGENESIS

(P 254) THE IMPACT OF MST (HIPPO KINASE) INHIBITION ON CHROMATIN ACCESSIBILITY AND ONCOGENIC PHENOTYPES IN FUSION-POSITIVE RHABDOMYOSARCOMA

(P 255) TRUNCATED FOS REDUCES OSTEOGENIC DIFFERENTIATION CAPACITY IN OSTEOID OSTEOMA AND OSTEOBLASTOMA

(P 256) TUMOR MUTATIONAL BURDEN AND MICROSATELLITE INSTABILITY IN LEIOMYOSARCOMA